B cells and cancer: To B or not to B? - Sorbonne Université Accéder directement au contenu
Article Dans Une Revue Journal of Experimental Medicine Année : 2021

B cells and cancer: To B or not to B?

Résumé

Whereas T cells have been considered the major immune cells of the tumor microenvironment able to induce tumor regression and control cancer clinical outcome, a burst of recent publications pointed to the fact that B cells may also play a prominent role. Activated in germinal centers of tertiary lymphoid structures, B cells can directly present tumor-associated antigens to T cells or produce antibodies that increase antigen presentation to T cells or kill tumor cells, resulting in a beneficial clinical impact. Immune complexes can also increase inflammation, angiogenesis, and immunosuppression via macrophage and complement activation, resulting in deleterious impact.
Fichier principal
Vignette du fichier
B cells JEM soumission revision final.pdf (364.16 Ko) Télécharger le fichier
Origine : Fichiers produits par l'(les) auteur(s)

Dates et versions

hal-03151879 , version 1 (25-02-2021)

Identifiants

Citer

Wolf Herman Fridman, Florent Petitprez, Maxime Meylan, Tom Wei-Wu Chen, Cheng-Ming Sun, et al.. B cells and cancer: To B or not to B?. Journal of Experimental Medicine, 2021, 218 (1), ⟨10.1084/jem.20200851⟩. ⟨hal-03151879⟩
50 Consultations
74 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More